ReviewFrontiers in pharmacology2018
Promising Antineoplastic Actions of Melatonin.
Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 66 citations in OpenAlex.
- Essential Hypertension and Oxidative Stress: Novel Future Perspectives.International journal of molecular sciences · 2022Trial
- Melatonin potentiates the antineoplastic effects of venetoclax in acute myeloid leukemia cells.Hematology, transfusion and cell therapy · 2026Article
- Reactive Oxygen Species in Breast Cancer: From Redox Dysregulation to ROS-Responsive Therapeutics.Cell biochemistry and function · 2026Review
- Multifaceted roles of melatonin in oncology: an insight into its therapeutic potential in cancer management.Inflammopharmacology · 2025Review
- Progress of melatonin in the treatment of intervertebral disc degeneration.Frontiers in physiology · 2025Review
- Pineal parenchymal tumor of intermediate differentiation: Case series and literature review: Is it time for a consensus?Surgical neurology international · 2025Article
- Significant Interaction between Melatonin and Titanium Bone Implants: Available Evidence and Future Research Directions.Current pharmaceutical biotechnology · 2025Review
- Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy (Review).International journal of oncology · 2024Review
- Unlocking New Therapeutic Options for Vincristine-Induced Neuropathic Pain: The Impact of Preclinical Research.Life (Basel, Switzerland) · 2024Review
- Melatonin Inhibits Endometriosis Growth via Specific Binding and Inhibition of EGFR Phosphorylation.Journal of pineal research · 2024Article
- Melatonin ameliorates inflammation-induced developmental defects of enamel by upregulating regulator of G protein signaling 2.Journal of dental sciences · 2024Article
- Anti-proliferative effect of melatonin in human hepatoma HepG2 cells occurs mainly through cell cycle arrest and inflammation inhibition.Scientific reports · 2023Article
- The Therapeutic Potential of Antioxidants in Chemotherapy-Induced Peripheral Neuropathy: Evidence from Preclinical and Clinical Studies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Review
- Characteristic of Ultrastructure of Mice B16 Melanoma Cells under the Influence of Different Lighting Regimes.Clocks & sleep · 2022Article
- Melatonin and cancer suppression: insights into its effects on DNA methylation.Cellular & molecular biology letters · 2022Article
- Role of melatonin in respiratory diseases (Review).Experimental and therapeutic medicine · 2022Review
- The interplay of pineal hormones and socioeconomic status leading to colorectal cancer disparity.Translational oncology · 2022Review
- The Prospective Application of Melatonin in Treating Epigenetic Dysfunctional Diseases.Frontiers in pharmacology · 2022Review
- The relationship between night shift work and breast cancer incidence: A systematic review and meta-analysis of observational studies.Open medicine (Warsaw, Poland) · 2022Article
- Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melatonin is an endogenous indoleamine with an incredible variety of properties and activities. In recent years, an increasing number of studies have investigated this indoleamine's interaction with cancerous cells. In particular, it seems that melatonin not only has the ability to improve the efficacy of many drugs used in chemotherapy but also has a direct inhibitory action on neoplastic cells. Many publications underlined the ability of melatonin to suppress the proliferation of various cancer cells or to modulate the expression of membrane receptors on these cells, thereby reducing tumor aggressiveness to metastasize. In addition, while melatonin has antiapoptotic actions in normal cells, in many cancer cells it has proapoptotic effects; these dichotomous actions have gained the interest of researchers. The increasing focus on melatonin in the field of oncology and the growing number of studies on this topic require a deep understanding of what we already know about the antineoplastic actions of melatonin. This information would be of value for potential use of melatonin against neoplastic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.